Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 28.69% | 31.70% | 26.80% | 23.67% | -4.84% |
| Total Depreciation and Amortization | 5.60% | 8.07% | 37.85% | 34.40% | 51.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -110.30% | -110.54% | -1,580.03% | -1,538.36% | 59.12% |
| Change in Net Operating Assets | -- | -- | -97.59% | -92.70% | -- |
| Cash from Operations | -50.15% | -48.98% | -33.73% | -35.36% | 24.34% |
| Capital Expenditure | 98.91% | 98.88% | 57.15% | 58.21% | -1,229.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -179.51% | -186.04% | -40.79% | -37.31% | 51.51% |
| Cash from Investing | -87.33% | -91.71% | -34.31% | -31.00% | 28.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -13.89% | -13.89% | -94.68% | -94.68% | 3.18% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.34% | -3.70% | -- | -- | -23.85% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -11.66% | -14.27% | -883.44% | -860.12% | -21.65% |
| Foreign Exchange rate Adjustments | 274.55% | 278.61% | -134.60% | -133.74% | -212.43% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -365.42% | -371.62% | -149.70% | -148.47% | 354.60% |